NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis $2.88 -0.15 (-4.95%) Closing price 04:00 PM EasternExtended Trading$2.88 0.00 (0.00%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Protalix BioTherapeutics Stock (NYSE:PLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PLX alerts:Sign Up Key Stats Today's Range$2.86▼$3.0850-Day Range$2.48▼$3.1352-Week Range$1.65▼$3.19Volume895,028 shsAverage Volume923,131 shsMarket Capitalization$242.84 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets. Protalix also develops additional plant-cell-produced drug candidates for conditions including gout and other diseases. Its work combines drug development with manufacturing using the ProCellEx platform, which is designed to produce therapeutic proteins in plant cells.AI Generated. May Contain Errors. Read More Protalix BioTherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScorePLX MarketRank™: 2.7809587217 of 5 starsProtalix BioTherapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 429th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialProtalix BioTherapeutics has a consensus price target of $12.00, representing about 316.7% upside from its current price of $2.88.Amount of Analyst CoverageProtalix BioTherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Protalix BioTherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3,000.00% Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 3,000.00% in the coming year, from $0.01 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is -22.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is -22.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PLX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.05 News SentimentProtalix BioTherapeutics has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Protalix BioTherapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for PLX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.70% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by Institutions16.53% of the stock of Protalix BioTherapeutics is held by institutions.Read more about Protalix BioTherapeutics' insider trading history. Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLX Stock News HeadlinesHC Wainwright Issues Pessimistic Estimate for PLX EarningsNovember 15 at 10:30 AM | americanbankingnews.comResearch Analysts Set Expectations for PLX FY2026 EarningsNovember 14 at 1:56 AM | americanbankingnews.comThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.November 17 at 1:00 AM | Porter & Company (Ad)PLX: Elfabrio Estimates Up, AgainNovember 11, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business ResultsNovember 11, 2026 | finanznachrichten.deProtalix sees $3.2B Fabry market by 2031 while targeting PRX-115 Phase II top-line results in H2 next yearNovember 10, 2026 | seekingalpha.comProtalix (PLX) Q3 2026 Earnings Call TranscriptNovember 10, 2026 | finance.yahoo.comProtalix Q3 Revenue Climbs; PRX-115 Topline Data Expected In H2 2027November 10, 2026 | rttnews.comSee More Headlines PLX Stock Analysis - Frequently Asked Questions How have PLX shares performed this year? Protalix BioTherapeutics' stock was trading at $1.80 at the beginning of 2026. Since then, PLX stock has increased by 60.0% and is now trading at $2.88. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) issued its quarterly earnings data on Friday, May, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. Protalix BioTherapeutics had a negative trailing twelve-month return on equity of 30.89% and a negative net margin of 21.03%. When did Protalix BioTherapeutics' stock split? Protalix BioTherapeutics's stock reverse split before market open on Friday, December 20th 2019.The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Protalix BioTherapeutics' major shareholders? Top institutional investors of Protalix BioTherapeutics include State Street Corp (1.44%), Goldman Sachs Group Inc. (1.05%), Marshall Wace LLP (0.37%) and Russell Investments Group Ltd. (0.31%). Insiders that own company stock include Aharon Schwartz, Dror Bashan and Amos Bar-Shalev. View institutional ownership trends. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protalix BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include BioLineRx (BLRX), NVIDIA (NVDA), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Plug Power (PLUG). Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PLX's financial health is in the Green zone, according to TradeSmith. PLX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:PLX CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees226Year Founded1994Price Target and Rating Average Price Target for Protalix BioTherapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+316.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.25 Trailing P/E RatioN/A Forward P/E Ratio9.29 P/E GrowthN/ANet Income$8.31 million Net Margins-21.03% Pretax Margin-21.00% Return on Equity-30.89% Return on Assets-11.74% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.27 Sales & Book Value Annual Sales$84.69 million Price / Sales2.87 Cash Flow$0.16 per share Price / Cash Flow17.80 Book Value$0.47 per share Price / Book6.13Miscellaneous Outstanding Shares84,319,000Free Float68,995,000Market Cap$242.84 million OptionableOptionable Beta0.01 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSE:PLX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.